TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Avenue Therapeutics ( (ATXI) ).
On November 5, 2025, Avenue Therapeutics and its subsidiary Baergic Bio entered into an agreement with Axsome Therapeutics for the acquisition of Baergic. Axsome acquired 100% of Baergic’s equity and global rights to BAER-101, now AXS-17, for an upfront payment and potential milestone payments totaling up to $82 million, along with royalties on future sales. This transaction is expected to accelerate the development of AXS-17 as a treatment for epilepsy, leveraging Axsome’s expertise. The deal also includes equity awards for Avenue’s executives, contingent on the transaction’s completion.
Spark’s Take on ATXI Stock
According to Spark, TipRanks’ AI Analyst, ATXI is a Underperform.
Avenue Therapeutics exhibits significant financial and operational challenges, notably with no revenue and ongoing losses, leading to a low financial performance score. The technical indicators point to a bearish trend with potential oversold conditions, but this does not offset the fundamental weaknesses. The valuation is constrained by negative earnings and lack of dividend yield. Overall, the stock holds substantial risks, reflected in its low score.
To see Spark’s full report on ATXI stock, click here.
More about Avenue Therapeutics
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The company is headquartered in Miami, FL and was founded by Fortress Biotech, Inc.
Average Trading Volume: 6,018
Technical Sentiment Signal: Sell
Current Market Cap: $2.39M
For an in-depth examination of ATXI stock, go to TipRanks’ Overview page.